News
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...
Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback